# Phase 8 — Retinal Disease Landscape

## Status

Phase 8 is complete. No Phase 9 or later feature was implemented.

## 1. Objective

Add a scientifically honest capability map describing which retinal disease-specific analysis the repository can support. The landscape is informational and does not create a multi-disease model, disease score, risk score, or additional disease predictions.

## 2. Repository inspection

The repository was searched for glaucoma, optic neuropathy, AMD, age-related macular degeneration, diabetic macular edema, DME, cataract, retinal vein occlusion, RVO, hypertensive retinopathy, macular degeneration, retinal detachment, pathological myopia, cup-to-disc ratio, macula, drusen, edema, multi-disease, multi-label, disease-specific labels, checkpoints, and evaluation assets.

The repository contains the active five-class DR classifier and related DR/progression/risk artifacts. No genuine local glaucoma, AMD, DME, cataract, RVO, hypertensive-retinopathy, retinal-detachment, pathological-myopia, or other additional disease classifier was identified.

The existing inactive risk artifact is not an additional disease model. The retrieval/progression artifacts are not disease-specific classifiers for those conditions. Phase 5 structure and Phase 6 lesion outputs are experimental image evidence and are not disease classifiers.

The populated labeled image source is `dataset/train.csv` with `dataset/train`; `dataset/valid` and `dataset/test` were empty during prior inspection. No additional paired disease labels or evaluation split were found.

## 3. Selected path

Path C was selected: an honest retinal disease capability map.

The isolated module is:

- `backend/disease_landscape/retinal_disease_landscape.py`

It describes repository evidence only and performs no inference.

## 4. Supported disease

### Diabetic Retinopathy

Status: `supported`

- Prediction available: yes.
- Model available: yes.
- Model: existing EfficientNet-B0 with root-level `dr_model.pth`.
- Labels: No Diabetic Retinopathy, Mild, Moderate, Severe, Proliferative DR.
- Label source: existing APTOS-style `dataset/train.csv` diagnosis labels.
- Current application scope: AI-assisted five-grade DR classification.

This is the existing disease-specific prediction and was not modified.

## 5. Unavailable diseases

The capability map explicitly marks these as unavailable, with no prediction or model available:

- Glaucoma
- Age-related Macular Degeneration
- Diabetic Macular Edema
- Cataract
- Retinal Vein Occlusion
- Hypertensive Retinopathy
- Retinal Detachment
- Pathological Myopia
- Other retinal diseases

An unavailable disease-specific model does not indicate absence of that disease. Disease-specific examination and testing remain necessary.

No probabilities, confidence values, risk estimates, or traffic-light disease indicators are generated.

## 6. API changes

Added:

```text
GET /api/disease-landscape
```

Added an additive `disease_landscape` field to `POST /api/analyze`.

The existing response fields remain present:

- prediction
- quality
- enhancement
- reliability
- structure
- lesion_evidence
- gradcam
- similar_cases
- progression_map
- progression_simulation
- evidence_summary
- errors

The landscape module does not alter prediction values or invoke any additional model.

## 7. Frontend changes

The existing `RetinalDiseaseLandscapeCard.jsx` presents:

- currently supported DR capability
- five supported DR labels
- additional conditions as unavailable capability gaps
- model/prediction availability
- repository-evidence notes
- explicit limitation that unavailable does not mean disease absence
- no disease score or probability

It is rendered separately from the DR prediction and evidence cards.

## 8. Real-image smoke test

The focused API regression uses `test_images/000c1434d8d7.png` and verifies:

- disease landscape endpoint returns HTTP 200
- full `/api/analyze` returns HTTP 200
- DR prediction remains Grade 2 / Moderate
- confidence remains 100.0
- disease landscape is present and reports only Diabetic Retinopathy as supported
- quality, enhancement, reliability, structure, lesion evidence, evidence summary, Grad-CAM, retrieval, progression, and errors remain present
- errors are empty

A separate longer end-to-end smoke command was stopped after model initialization when it exceeded the safety window; the passing focused API test provides the completed regression assertion without claiming an additional result.

This sample is not clinical validation.

## 9. Tests

Focused landscape tests:

```powershell
.\\venv\\Scripts\\python.exe -m pytest -q tests/test_retinal_disease_landscape.py tests/test_disease_landscape_api.py
```

Result: `4 passed`.

Complete focused test suite:

```powershell
.\\venv\\Scripts\\python.exe -m pytest -q tests
```

Result: `57 passed`.

## 10. Frontend build

```powershell
npm --prefix frontend run build
```

Result: Vite production build passed.

## 11. Prediction-integrity verification

The disease landscape is static capability metadata. It does not receive or transform classifier logits and does not modify:

- grade
- confidence
- risk level
- Grad-CAM
- quality
- enhancement
- reliability
- structure
- lesion evidence
- retrieval
- progression
- evidence summary

The verified sample remains Grade 2 / Moderate with confidence 100.0.

## 12. Files added

- `backend/disease_landscape/__init__.py`
- `backend/disease_landscape/retinal_disease_landscape.py`
- `frontend/src/components/RetinalDiseaseLandscapeCard.jsx`
- `tests/test_retinal_disease_landscape.py`
- `tests/test_disease_landscape_api.py`
- `PHASE_8_RETINAL_DISEASE_LANDSCAPE_CHECKPOINT.md`

## 13. Files modified

- `backend/main.py`
- `frontend/src/types.ts`

The existing partial frontend wiring and styles were preserved; no classifier, model weights, preprocessing, prediction logic, Phase 2–7 algorithm, retrieval, progression, Grad-CAM, or PDF implementation was changed.

## 14. Scientific limitations

- Only diabetic retinopathy grading is defensibly supported by the current repository evidence.
- No additional disease-specific model or paired disease labels were available.
- No external validation or clinical validation was performed.
- Capability status is not a statement about disease presence or absence.
- The DR checkpoint's broader clinical generalization remains limited by the baseline data/provenance constraints.
- Experimental structure and lesion evidence are not disease classifiers and are not converted into disease predictions.
- No multi-disease score, disease probability, retinal-health score, or risk score was created.

Phase 9 and all later phases were not implemented.
